Amgen’s Otezla notches another PhIII win; Califf earns advocacy groups’ stamp of approval

Amgen’s blockbuster Otezla just racked up another Phase III win as it looks to continue expanding on its multibillion-dollar revenue stream.

The drug hit the primary endpoint in a trial researching its use in moderate to severe genital psoriasis, Amgen announced in the topline readout Wednesday...

Click to view original post